Extensively studying and subtyping NSCLC through genetic analyses enables molecular understanding, resulting in more effective therapeutic options, significantly reducing toxicity profiles through target treatment of NSCLC subtypes (e.g., EGFR, ALK, and ROS1). Here, ALK is linked to non-small cell lung carcinoma.